Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARDA backs Medicines/Rempex antibiotic with $90m award

This article was originally published in Scrip

Executive Summary

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Rempex Pharmaceuticals, a wholly owned subsidiary of The Medicines Company (MDCO), a contract worth up to $90m to support the development of its investigational antibiotic Carbavance to treat antibiotic-resistant infections and act as an agent against two bioterrorism threats – melioidosis and glanders, two highly deadly infections.

Advertisement

Related Content

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024334

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel